VerifiedPharmaceutical Manufacturing· Founded 2014

Paradigm Biopharmaceuticals

Paradigm’s (ASX:PAR) immediate commercial focus is the development of pentosan polysulfate sodium (PPS) for the treatment of osteoarthritis (OA). This is a global unmet need and we have advanced to phase 3 trials in the space. Addressing all aspects of the disease: inflammation, pain, and regeneration, the non-opioid PPS has genuine disease-modifying potential.

7-day free trial · no credit card

Melbourne, Australia25(11 to 50)2014paradigmbiopharma.com LinkedIn

Verified contacts

19

available on Kipplo

LinkedIn employees

25

11 to 50 range

Open roles

—

no listings

Distinct roles

16

indexed titles

Tech stack

0

tools in use

Monthly traffic

—

organic / mo

Sign up free to see all 19 verified contacts at Paradigm Biopharmaceuticals

Free for 7 days · 50 credits · no card · only pay for verified records.

Decision-makers and verified team members

19 contacts with verified email or phone · masked until revealed.

Sign up free →

Showing 9 of 19 verified contacts

Top roles at Paradigm Biopharmaceuticals

16 distinct titles indexed · top 10 shown.

3clinical operations lead
1biometrics manager
1ceo
1chief executive officer
1chief medical officer
1chief scientific officer
1clinical outcomes consultant
1director of investor relations
1director of regulatory affairs
1global head of translational development
+6more titles

Sign up to unlock all 19 contacts at Paradigm Biopharmaceuticals

Free for 7 days · 50 credits · no card · only pay for verified records.

Sign up to reveal 19 verified contacts at Paradigm Biopharmaceuticals

7-day trial · no credit card · cancel anytime · only pay for verified records.

Sign up free See pricing

Trusted by sales, marketing, and GTM engineering teams.

Paradigm Biopharmaceuticals | Kipplo Discover